

CORRECTION

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

David L. Chan, Nick Pavlakis, Jeremy Shapiro, Timothy J. Price, Christos S. Karapetis, Niall C. Tebbutt, Eva Segelov

There is an error in reference 22. The correct reference is: Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol*. 2010 Nov 1;28(31):4706-13.

[Fig 5](#) is incorrect. The authors have provided a corrected version here.



OPEN ACCESS

Citation: Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, et al. (2015) Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. *PLoS ONE* 10(9): e0138916. doi:10.1371/journal.pone.0138916

Published: September 25, 2015

Copyright: © 2015 Chan et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Fig 5. OS outcomes for EGFR-I by chemotherapy backbone—extended RAS analysis.

doi:10.1371/journal.pone.0138916.g001

Reference

1. Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, et al. (2015) Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS ONE 10(8): e0135599. doi:[10.1371/journal.pone.0135599](https://doi.org/10.1371/journal.pone.0135599) PMID: [26275292](https://pubmed.ncbi.nlm.nih.gov/26275292/)